DE10206995A1 - Two-part micronutrient product, useful as a dietary supplement and for treatment of disease, comprises a probiotic component and a second component containing prebiotics, trace elements, vitamins and secondary plant substances - Google Patents
Two-part micronutrient product, useful as a dietary supplement and for treatment of disease, comprises a probiotic component and a second component containing prebiotics, trace elements, vitamins and secondary plant substancesInfo
- Publication number
- DE10206995A1 DE10206995A1 DE10206995A DE10206995A DE10206995A1 DE 10206995 A1 DE10206995 A1 DE 10206995A1 DE 10206995 A DE10206995 A DE 10206995A DE 10206995 A DE10206995 A DE 10206995A DE 10206995 A1 DE10206995 A1 DE 10206995A1
- Authority
- DE
- Germany
- Prior art keywords
- vitamin
- probiotics
- combination product
- lactobacillus
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 90
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 90
- 239000011785 micronutrient Substances 0.000 title claims abstract description 64
- 235000013369 micronutrients Nutrition 0.000 title claims abstract description 64
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 39
- 229940088594 vitamin Drugs 0.000 title claims abstract description 21
- 229930003231 vitamin Natural products 0.000 title claims abstract description 21
- 235000013343 vitamin Nutrition 0.000 title claims abstract description 21
- 239000011782 vitamin Substances 0.000 title claims abstract description 21
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 20
- 239000011573 trace mineral Substances 0.000 title claims abstract description 20
- 235000013619 trace mineral Nutrition 0.000 title claims abstract description 20
- 239000000126 substance Substances 0.000 title claims abstract description 16
- 239000000047 product Substances 0.000 title claims description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 10
- 201000010099 disease Diseases 0.000 title claims description 4
- 235000015872 dietary supplement Nutrition 0.000 title claims description 3
- 239000013066 combination product Substances 0.000 claims description 49
- 229940127555 combination product Drugs 0.000 claims description 49
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 32
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 28
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 26
- 241000194031 Enterococcus faecium Species 0.000 claims description 21
- 229920001202 Inulin Polymers 0.000 claims description 21
- 229940029339 inulin Drugs 0.000 claims description 21
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 21
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 20
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 20
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 18
- 239000004480 active ingredient Substances 0.000 claims description 17
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 16
- 241000894006 Bacteria Species 0.000 claims description 16
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 16
- 239000004310 lactic acid Substances 0.000 claims description 16
- 235000014655 lactic acid Nutrition 0.000 claims description 16
- 235000019154 vitamin C Nutrition 0.000 claims description 15
- 239000011718 vitamin C Substances 0.000 claims description 15
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 14
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 14
- 229930003268 Vitamin C Natural products 0.000 claims description 14
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 13
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 13
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 239000011701 zinc Substances 0.000 claims description 13
- 229910052725 zinc Inorganic materials 0.000 claims description 13
- 235000016804 zinc Nutrition 0.000 claims description 13
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 12
- 244000057717 Streptococcus lactis Species 0.000 claims description 12
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 12
- 229910052742 iron Inorganic materials 0.000 claims description 12
- 239000011669 selenium Substances 0.000 claims description 12
- 229910052711 selenium Inorganic materials 0.000 claims description 12
- 235000011649 selenium Nutrition 0.000 claims description 12
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 12
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 11
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 11
- 244000199866 Lactobacillus casei Species 0.000 claims description 11
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 11
- 241000186869 Lactobacillus salivarius Species 0.000 claims description 11
- 229910052802 copper Inorganic materials 0.000 claims description 11
- 239000010949 copper Substances 0.000 claims description 11
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 11
- 229940017800 lactobacillus casei Drugs 0.000 claims description 11
- 229910052750 molybdenum Inorganic materials 0.000 claims description 11
- 239000011733 molybdenum Substances 0.000 claims description 11
- 235000019165 vitamin E Nutrition 0.000 claims description 11
- 239000011709 vitamin E Substances 0.000 claims description 11
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 10
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 10
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 10
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 10
- 229930003427 Vitamin E Natural products 0.000 claims description 10
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 10
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 10
- 229960002685 biotin Drugs 0.000 claims description 10
- 239000011616 biotin Substances 0.000 claims description 10
- 235000020958 biotin Nutrition 0.000 claims description 10
- 229910052804 chromium Inorganic materials 0.000 claims description 10
- 239000011651 chromium Substances 0.000 claims description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 10
- 229960003512 nicotinic acid Drugs 0.000 claims description 10
- 235000001968 nicotinic acid Nutrition 0.000 claims description 10
- 239000011664 nicotinic acid Substances 0.000 claims description 10
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 claims description 10
- 239000011772 phylloquinone Substances 0.000 claims description 10
- 235000019155 vitamin A Nutrition 0.000 claims description 10
- 239000011719 vitamin A Substances 0.000 claims description 10
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 10
- 229940046009 vitamin E Drugs 0.000 claims description 10
- 229940045997 vitamin a Drugs 0.000 claims description 10
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 9
- 229940093797 bioflavonoids Drugs 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 9
- 229960000304 folic acid Drugs 0.000 claims description 9
- 239000011724 folic acid Substances 0.000 claims description 9
- 235000019152 folic acid Nutrition 0.000 claims description 9
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 claims description 8
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 8
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 8
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 8
- 235000021466 carotenoid Nutrition 0.000 claims description 8
- 229940055726 pantothenic acid Drugs 0.000 claims description 8
- 239000011713 pantothenic acid Substances 0.000 claims description 8
- 235000019161 pantothenic acid Nutrition 0.000 claims description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims description 7
- 235000005911 diet Nutrition 0.000 claims description 7
- 239000011630 iodine Substances 0.000 claims description 7
- 229910052740 iodine Inorganic materials 0.000 claims description 7
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 6
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 6
- 150000001747 carotenoids Chemical class 0.000 claims description 6
- 230000000378 dietary effect Effects 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 235000017807 phytochemicals Nutrition 0.000 claims description 6
- 229930000223 plant secondary metabolite Natural products 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- -1 iodine, carotenoids Chemical class 0.000 claims description 5
- 229920002261 Corn starch Polymers 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 229920002774 Maltodextrin Polymers 0.000 claims description 4
- 239000005913 Maltodextrin Substances 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 239000008120 corn starch Substances 0.000 claims description 4
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 4
- 229940035034 maltodextrin Drugs 0.000 claims description 4
- 229910052748 manganese Inorganic materials 0.000 claims description 4
- 239000011572 manganese Substances 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 3
- 244000215068 Acacia senegal Species 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 206010016946 Food allergy Diseases 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 229920000084 Gum arabic Polymers 0.000 claims description 3
- 235000010489 acacia gum Nutrition 0.000 claims description 3
- 239000000205 acacia gum Substances 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 3
- 208000007386 hepatic encephalopathy Diseases 0.000 claims description 3
- 229940085605 saccharin sodium Drugs 0.000 claims description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 2
- 241000193755 Bacillus cereus Species 0.000 claims description 2
- 229920002498 Beta-glucan Polymers 0.000 claims description 2
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 2
- 101000782236 Bothrops leucurus Thrombin-like enzyme leucurobin Proteins 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 241000194032 Enterococcus faecalis Species 0.000 claims description 2
- 241000588724 Escherichia coli Species 0.000 claims description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 2
- 208000005577 Gastroenteritis Diseases 0.000 claims description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 241000218492 Lactobacillus crispatus Species 0.000 claims description 2
- 241000509544 Lactobacillus gallinarum Species 0.000 claims description 2
- 241000186606 Lactobacillus gasseri Species 0.000 claims description 2
- 241001468157 Lactobacillus johnsonii Species 0.000 claims description 2
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 2
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 2
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 2
- 201000010538 Lactose Intolerance Diseases 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 241000186428 Propionibacterium freudenreichii Species 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 2
- 241000204115 Sporolactobacillus inulinus Species 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 201000009961 allergic asthma Diseases 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 229940032049 enterococcus faecalis Drugs 0.000 claims description 2
- 235000020932 food allergy Nutrition 0.000 claims description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 2
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 230000000873 masking effect Effects 0.000 claims description 2
- 239000007968 orange flavor Substances 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 claims 2
- 241000186016 Bifidobacterium bifidum Species 0.000 claims 1
- 241001608472 Bifidobacterium longum Species 0.000 claims 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims 1
- 239000011795 alpha-carotene Substances 0.000 claims 1
- 235000003903 alpha-carotene Nutrition 0.000 claims 1
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 claims 1
- 235000013734 beta-carotene Nutrition 0.000 claims 1
- 239000011648 beta-carotene Substances 0.000 claims 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims 1
- 229960002747 betacarotene Drugs 0.000 claims 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims 1
- 229940009291 bifidobacterium longum Drugs 0.000 claims 1
- 235000020299 breve Nutrition 0.000 claims 1
- 229940070404 citrus bioflavonoids Drugs 0.000 claims 1
- 229940099112 cornstarch Drugs 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 229960001031 glucose Drugs 0.000 claims 1
- 235000012680 lutein Nutrition 0.000 claims 1
- 229960005375 lutein Drugs 0.000 claims 1
- 239000001656 lutein Substances 0.000 claims 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims 1
- 235000012661 lycopene Nutrition 0.000 claims 1
- 239000001751 lycopene Substances 0.000 claims 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims 1
- 229960004999 lycopene Drugs 0.000 claims 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 description 18
- 210000000936 intestine Anatomy 0.000 description 15
- 210000001035 gastrointestinal tract Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 3
- 230000002475 laxative effect Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002535 acidifier Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241001591005 Siga Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000020802 micronutrient deficiency Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Die vorliegende Erfindung betrifft ein Pro- und Prebiotika enthaltendes Mikronährstoffkombinationsprodukt, insbesondere mit Enterococcus faecium, sowie dessen Verwendung als diätetisches Lebensmittel für besondere medizinische Zwecke. Das erfindungsgemäße Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika (Orthomol® Immun Pro) ist zur diätetischen Behandlung bei Störungen der Darmflora und des darmassoziierten Immunsystems, z. B. bei Allergien, nach Chemo- und Strahlentherapie und nach Antibiotikaeinnahme geeignet. Das erfindungsgemäße Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika unterstützt insbesondere die Abwehrkräfte. The present invention relates to a containing prebiotics Micronutrient combination product, in particular with Enterococcus faecium, and its Use as a dietetic food for special medical purposes. The Micronutrient combination product according to the invention with prebiotics and prebiotics (Orthomol® Immun Pro) is for dietary treatment of disorders of the intestinal flora and the gut-associated immune system, e.g. B. for allergies, after chemotherapy and radiation therapy and suitable after taking antibiotics. The invention Micronutrient combination product with probiotics and prebiotics particularly supports the Immunity.
Es ist allgemein bekannt, dass ein intaktes Immunsystem ein wichtiger Faktor der menschlichen Gesundheit ist und eine funktionierende körpereigene Abwehr den besten Schutz gegenüber Angriffen von Viren, Bakterien und Umweltschadstoffen bietet. Der Zustand des Immunsystems hängt insbesondere von einer ausreichenden nutritiven Zufuhr von Mikronährstoffen ab. It is well known that an intact immune system is an important factor in the human health is the best and a functioning defense system Offers protection against attacks by viruses, bacteria and environmental pollutants. The The state of the immune system depends in particular on an adequate nutritional intake on micronutrients.
Die Resorption von Mikronährstoffen aus dem Darm wird durch viele Erkrankungen, Medikamente sowie durch Stress behindert. Insbesondere stressbedingte Ernährungsgewohnheiten können vielfach unbemerkt zu Defiziten in der Vitamin- und Mineralstoffversorgung des Organismus führen und als Folge negative Rückwirkungen auf den allgemeinen Gesundheitszustand zeigen. The absorption of micronutrients from the intestine is caused by many diseases, Medication as well as hindered by stress. Especially stress-related Dietary habits can often go unnoticed to deficits in the vitamin and Mineral supply of the organism and, as a result, negative repercussions show the general state of health.
Die im Stand der Technik bekannten Vitaminprodukte enthalten verschiedenste Zusammensetzungen von Vitaminen und Spurenelementen, die jedoch nicht auf eine ganzheitliche Stimulation des gesamten Immunsystems ausgerichtet sind. So enthalten ein Großteil dieser Zusammensetzungen hohe Anteile an antioxidativ wirkenden Vitaminen und Spurenelementen, jedoch keine probiotischen Kulturen. Ein Nachteil dieser Produkte ist ihre mangelnde Berücksichtigung des darmassoziierten Immunsystems, das ein wichtiges Organ der körpereigenen Immunabwehr ist. The vitamin products known in the prior art contain a wide variety Compositions of vitamins and trace elements, but not based on a holistic Stimulation of the entire immune system. So a lot of these contain Compositions high levels of vitamins and antioxidants Trace elements, but not probiotic cultures. A disadvantage of these products is theirs lack of consideration of the gut-associated immune system, which is an important organ the body's immune system.
Die Tagesdosis erhältlicher Produkte zur Unterstützung des Immunsystems wird vielfach in Form einer einzelnen Tablette oder Kapsel verabreicht, um dem Bedürfnis des Verbrauchers nach möglichst einfacher Anwendung entgegen zu kommen, ohne möglichen negativen Interaktionen der Inhaltsstoffe ausreichend Rechnung zu tragen. Ein Nachteil der erhältlichen Produkte besteht darin, dass eine Kombination von probiotischen Kulturen und des Prebiotikums Inulin gegebenenfalls mit von Vitamin C bei gemeinsamer oraler Verabreichung eine stark abführende Wirkung hat. The daily dose of products available to support the immune system is often in Form of a single tablet or capsule administered to the consumer's need to accommodate after the simplest possible application, without possible negative Interactions of the ingredients take sufficient account. A disadvantage of the available Products is a combination of probiotic cultures and the Prebiotics inulin, if necessary, with vitamin C in common oral Administration has a strong laxative effect.
Ein weiterer Nachteil ist, dass bei vielen Produkten Magensäure zu einer weitreichenden Zersetzung der probiotischen Kulturen, wie Milchsäurebakterien, führt. Die Menge an probiotischen Kulturen, die letztlich den Darm erreicht, ist verschwindend gering. Darüber hinaus wird die Anzahl der lebend den Darm erreichenden probiotischen Kulturen angesichts der am Wirkort herrschenden schlechten Wachstums- bzw. Lebensbedingungen noch weiter reduziert, so dass ein starker Aktivitätsverlust innerhalb kurzer Zeit eintritt. Another disadvantage is that with many products gastric acid becomes far-reaching Decomposes the probiotic cultures, such as lactic acid bacteria. The amount of probiotic cultures that ultimately reach the gut are negligible. About that In addition, the number of probiotic cultures living in the intestine is considered the poor growth or living conditions prevailing at the site of action reduced, so that a strong loss of activity occurs within a short time.
Es besteht daher ein Bedarf an einem Mikronährstoffkombinationsprodukt, bei dem eine möglichst hohe Anzahl an probiotischen Kulturen den Wirkort lebend erreicht und die gleichzeitig eine wesentlich verlängerte durchschnittliche Lebensdauer aufweisen. Weiterhin besteht ein Bedarf, ein hinsichtlich seiner Zusammensetzung optimal formuliertes bzw. dosiertes Mikronährstoffkombinationsprodukt mit einer verbesserten nutritiven Immunstimulierung zur Verfügung zu stellen. Zudem besteht Bedarf an einem Mittel, das eine abführende Wirkung zuverlässig vermeidet. There is therefore a need for a micronutrient combination product in which one as many probiotic cultures as possible reach the site of action alive and the at the same time have a significantly longer average lifespan. Farther there is a need for an optimally formulated or dosed micronutrient combination product with an improved nutritive To provide immune stimulation. There is also a need for a means that reliably avoids a laxative effect.
Es ist daher die Aufgabe der vorliegenden Erfindung, ein Mikronährstoffkombinationsprodukt zur Verfügung zu stellen, dass die vorgenannten Nachteile des Standes der Technik überwindet. Insbesondere ist es die Aufgabe der vorliegenden Erfindung, ein Mittel zur Verfügung zu stellen, dass eine umfassende nutritive Stimulierung des Immunsystems bietet. It is therefore the object of the present invention to provide a micronutrient combination product to provide that the aforementioned disadvantages of the prior art overcomes. In particular, it is the object of the present invention to provide a means for To provide comprehensive nutritional stimulation of the immune system.
Diese Aufgabe wird durch ein hinsichtlich seiner Bestandteile optimiert formuliertes Probiotika enthaltendes Mikronährstoffkombinationsprodukt gelöst, das mindestens zwei Produktanteile mit unterschiedlicher Zusammensetzung umfasst, wobei ein erster Anteil als wirksame Bestandteile Probiotika umfasst und ein zweiter Anteil als wirksame Bestandteile Prebiotika bzw. Präbiotika, Spurenelemente, Vitamine und sekundäre Pflanzenstoffe umfasst. This task is formulated in an optimized way with regard to its components Micronutrient combination product containing probiotics dissolved, the at least two Includes product portions with different compositions, with a first portion as active ingredients includes probiotics and a second portion as active ingredients Includes prebiotics or prebiotics, trace elements, vitamins and phytochemicals.
Besonders bevorzugt wird diese Aufgabe durch ein hinsichtlich seiner Bestandteile optimiert formuliertes Probiotika enthaltendes Mikronährstoffkombinationsprodukt gelöst, das mindestens zwei Produktanteile mit unterschiedlicher Zusammensetzung umfasst, wobei ein erstes Produkt als wirksame Bestandteile ausschließlich Probiotika umfasst und das zweite Produkt frei von Probiotika ist und als wirksame Bestandteile Prebiotika, Spurenelemente, Vitamine und sekundäre Pflanzenstoffe umfasst. This task is particularly preferably optimized with regard to its components formulated probiotics containing micronutrient combination product, the comprises at least two product parts with different compositions, one the first product contains only probiotics as active ingredients and the second Product is free from probiotics and as effective components prebiotics, trace elements, Includes vitamins and phytochemicals.
Die probiotischen Kulturen des Probiotika enthaltenden Mikronährstoffkombinationsproduktes sind ausgewählt aus der Gruppe umfassend Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus crispatus, Lactobacillus gallinarum, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus salivarius, Bifidobacterium adolescentis, Bifidobacterium animalis, Bifidobactenum bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobactenum lactis, Bifidobactenum longum, Enterococcus faecalis, Enterococcus faecium, Lactococcus lactis, Leuc. mesenteroides, Ped. acidilactici, Sporolactobacillus inulinus, Strep. thermophilus, Bacillus cereus, Escherichia coli, Propionibacterium freudenreichii und/oder Saccharomyces cerevisiae, vorzugsweise Bifidobacterium lactis, Bifidobactenum animalis, Lactococcus lactis, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus salivanus und/oder Enterococcus faecium. The probiotic cultures of probiotics Micronutrient combination products are selected from the group comprising Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus crispatus, Lactobacillus gallinarum, Lactobacillus gasseri, Lactobacillus johnsonii, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus salivarius, Bifidobacterium adolescentis, Bifidobacterium animalis, Bifidobactenum bifidum, Bifidobacterium breve, Bifidobacterium infantis, Bifidobactenum lactis, Bifidobactenum longum, Enterococcus faecalis, Enterococcus faecium, Lactococcus lactis, Leuc. mesenteroides, Ped. acidilactici, Sporolactobacillus inulinus, Strep. thermophilus, Bacillus cereus, Escherichia coli, Propionibacterium freudenreichii and / or Saccharomyces cerevisiae, preferably Bifidobacterium lactis, Bifidobactenum animalis, Lactococcus lactis, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus salivanus and / or Enterococcus faecium.
Ein besonderer Vorteil ist, dass durch die erfindungsgemäße Verwendung von probiotischen Kulturen, umfassend Milchsäurebakterien, wie Bifidobactenum lactis, Bifidobactenum animalis, Lactococcus lactis, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus salivarius und/oder Enterococcus faecium, in Folge gebildeter Milchsäure der pH-Wert im Darmtrakt gesenkt wird, wodurch Spurenelemente, insbesondere Eisen und Zink, besser in Lösung gehen und hierdurch in erhöhtem Maße resorbiert werden können. Darüber hinaus können die probiotischen Kulturen die resorbierende Oberfläche des Darms vergrößern und somit weiterhin zu einer Erhöhung der Resorption beitragen. A particular advantage is that the use of probiotic according to the invention Cultures including lactic acid bacteria such as Bifidobactenum lactis, Bifidobactenum animalis, Lactococcus lactis, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus salivarius and / or Enterococcus faecium, as a result of the lactic acid formed the pH value in the Intestinal tract is lowered, making trace elements, especially iron and zinc, better in Go solution and can thereby be absorbed to an increased extent. Furthermore probiotic cultures can enlarge the resorbing surface of the intestine and thus continue to contribute to an increase in absorption.
Besonders bevorzugt ist bei dem erfindungsgemäßen Probiotika enthaltenden Mikronährstoffkombinationsprodukt die Kombination Enterococcus faecium und Milchsäurebakterien. Is particularly preferred in the probiotics according to the invention Micronutrient combination product the combination Enterococcus faecium and Lactic acid bacteria.
Es hat sich überraschend gezeigt, dass insbesondere das erfindungsgemäß verwendete probiotische Bakterium Enterococcus faecium einen deutlich verbessernden Einfluss auf die Wirksamkeit der Milchsäurebakterien zeigt. Enterococcus faecium kann den pH-Wert des Darmes schon im vorderen Bereich des Darmes ausgehend vom Magen senken. Bedingt durch diese Vorsäuerung wird die Wachstumsrate bzw. -geschwindigkeit der probiotischen Kulturen, insbesondere der Milchsäurebakterien, deutlich gesteigert, so dass der pH-Wert im Darm weiter sinkt, was zu einer zusätzlichen Erhöhung der Vermehrungsrate der probiotischen Kulturen im Darm führt. It has surprisingly been found that in particular that used according to the invention probiotic bacterium Enterococcus faecium has a significantly improving influence on the Effectiveness of lactic acid bacteria shows. Enterococcus faecium can control the pH of the Lower the intestine in the front area of the intestine starting from the stomach. conditioned through this pre-acidification the growth rate or rate of the probiotic Cultures, especially the lactic acid bacteria, increased significantly, so that the pH in the The intestine continues to drop, causing an additional increase in the rate of multiplication of the leads to probiotic cultures in the intestine.
Ein weiterer vorteilhafter Effekt des erfindungsgemäßen Mikronährstoffkombinationsproduktes ist, dass die erhöhte Anzahl lebender Milchsäurebakterien im Darm das Eindringen von Viren, pathogenen Bakterien und Toxinen vermindert. Überraschend hat sich gezeigt, dass die Verwendung des erfindungsgemäßen Gemischs der probiotischen Bakterienstämme als ergänzende Ernährung, insbesondere umfassend mit der Verwendung des Stammes Enterococcus faecium, eine deutliche Steigerung der Produktion spezifischer Antikörper, wie sIgA und natürlicher Killerzellen bewirkt. Another advantageous effect of the invention Micronutrient combination product is that the increased number of living Lactic acid bacteria in the intestine the entry of viruses, pathogenic bacteria and toxins reduced. Surprisingly, it has been shown that the use of the invention Mixture of the probiotic bacterial strains as a supplementary nutrition, in particular extensive with the use of the strain Enterococcus faecium, a clear Increase in the production of specific antibodies, such as sIgA and natural killer cells causes.
Das Probiotika enthaltende Mikronährstoffkombinationsprodukt umfasst erfindungsgemäß Prebiotika ausgewählt aus der Gruppe umfassend Inulin, Fructooligosaccharide und β-Glucan. The micronutrient combination product containing probiotics comprises according to the invention Prebiotics selected from the group consisting of inulin, fructooligosaccharides and β-glucan.
Es hat sich überraschend gezeigt, dass das erfindungsgemäße Mikronährstoffkombinationsprodukt durch die Zugabe des Prebiotikums Inulin zum Überleben der probiotischen Kulturen im Darm beiträgt. It has surprisingly been found that the inventive Micronutrient combination product by adding the prebiotic inulin to the Survival of probiotic cultures in the gut helps.
Die Vitamine, die das Probiotika enthaltende Mikronährstoffkombinationsprodukt umfasst, sind erfindungsgemäß ausgewählt aus der Gruppe umfassend Vitamin A, Vitamin C, natürliches Vitamin E, Vitamin B1, Vitamin B2, Niacin, Vitamin B6, Vitamin B12, Vitamin K1, Vitamin D3, Folsäure, Panthothensäure und/oder Biotin. According to the invention, the vitamins which the probiotics-containing micronutrient combination product comprises are selected from the group comprising vitamin A, vitamin C, natural vitamin E, vitamin B 1 , vitamin B 2 , niacin, vitamin B 6 , vitamin B 12 , vitamin K 1 , vitamin D 3 , folic acid, pantothenic acid and / or biotin.
Die sekundären Pflanzenstoffe des Probiotika enthaltenden Mikronährstoffkombinationsprodukt sind erfindungsgemäß ausgewählt aus der Gruppe umfassend Carotinoide und Bioflavonoide The phytochemical containing phytochemicals Micronutrient combination products are selected from the group according to the invention including carotenoids and bioflavonoids
Vorteilhaft ist weiterhin die optimierte Zusammensetzung bezüglich des Gehalts an Vitamin C, Inulin und probiotischen Kulturen, wodurch eine abführende Wirkung auf Grund zu hoher Vitamin C-Gehalte bei gleichzeitiger Anwesenheit von Inulin und probiotischen Kulturen vermieden wird. Zudem ist eine Kombination von Vitamin C und Bioflavonoiden von Vorteil, wodurch die ernährungsühysiologische Aktivität des Vitamin C und dessen Funktion vorteilhaft ergänzt werden kann. The optimized composition with regard to the vitamin content is also advantageous C, inulin and probiotic cultures, causing a laxative effect due to being too high Vitamin C levels in the presence of inulin and probiotic cultures is avoided. A combination of vitamin C and bioflavonoids is also advantageous, which increases the nutritional-physiological activity of vitamin C and its function can be advantageously added.
Die Spurenelemente, die das Probiotika enthaltende Mikronährstoffkombinationsprodukt umfasst, sind ausgewählt aus der Gruppe umfassend Calcium, Selen, Eisen, Zink, Mangan, Kupfer, Chrom, Molybdän, Iod, Phosphor, Magnesium, Kalium und/oder Chlorid, vorzugsweise Selen, Eisen, Zink, Mangan, Kupfer, Chrom, Molybdän und/oder Iod. The trace elements that make up the probiotics-containing micronutrient combination product are selected from the group comprising calcium, selenium, iron, zinc, manganese, Copper, chromium, molybdenum, iodine, phosphorus, magnesium, potassium and / or chloride, preferably selenium, iron, zinc, manganese, copper, chromium, molybdenum and / or iodine.
Es hat sich gezeigt, dass durch den optimierten Gehalt an Spurenelementen, wie Selen, Eisen, Zink, Mangan, Kupfer, Chrom, Molybdän und/oder Iod eine deutlich bessere Stimulierung des Immunsystems unter Einbeziehung des Darmassoziierten Immunsystems und dadurch eine Erhöhung der Abwehrkräfte eintritt. Dies ist zur diätetischen Behandlung bei Störungen der Darmflora und des darmassoziierten Immunsystems wichtig, z. B. bei Allergien, nach Chemo- und Strahlentherapie, nach Antibiotikaeinnahme. It has been shown that the optimized content of trace elements such as selenium, iron, Zinc, manganese, copper, chromium, molybdenum and / or iodine a significantly better stimulation of the immune system including the gut-associated immune system and thereby an increase in the body's defenses. This is for dietary treatment for disorders the intestinal flora and the gut-associated immune system are important, e.g. B. for allergies, after Chemotherapy and radiation therapy after taking antibiotics.
Der Begriff "diätetische Behandlung" ist in der EU-Richtlinie 1999/21/EG, die seit 01.01.2002 als 10. Verordnung zur Änderung der Diätverordnung in deutsches Recht umgesetzt worden, näher erläutert. The term "dietary treatment" has been in EU Directive 1999/21 / EC since 01.01.2002 as the 10th regulation to change the diet regulation into German law implemented, explained in more detail.
Ein weiterer Vorteil des erfindungsgemäßen Mikronährstoffkombinationsproduktes besteht in der synergistischen Wirkung im Hinblick auf eine umfassende ganzheitliche Stimulierung des körpereigenen Immunsystems. Das Immunsystem wird durch die optimierte Kombination der Vitamine und Spurenelemente, insbesondere der Vitamine C und E, Selen und Zink, gestärkt. Darüber hinaus wird der Darm, der einen wichtigen Teil des menschlichen Immunsystems darstellt, miteinbezogen. Die verlängerte Lebensdauer der probiotischen Kulturen und des damit bedingten niedrigen pH-Wertes führen im Dünndarm zu einer verbesserten Resorption der Spurenelemente sowie darüber hinaus zu einer erhöhten eigenen Synthese von Vitaminen, z. B. Thiamin, Riboflavin Vitamin B12 und Folsäure, die der Mensch zusätzlich resorbiert. Another advantage of the micronutrient combination product according to the invention is the synergistic effect with regard to a comprehensive holistic stimulation of the body's immune system. The immune system is strengthened by the optimized combination of vitamins and trace elements, in particular vitamins C and E, selenium and zinc. The intestine, which is an important part of the human immune system, is also involved. The prolonged lifespan of the probiotic cultures and the resulting low pH lead to an improved absorption of the trace elements in the small intestine as well as to an increased own synthesis of vitamins, e.g. B. thiamine, riboflavin vitamin B 12 and folic acid, which humans are additionally absorbed.
Die Produkte des Probiotika enthaltenden Mikronährstoffkombinationsprodukts können fest-, flüssig und/oder gelförmig vorliegen. The products of the micronutrient combination product containing probiotics can be solid, present in liquid and / or gel form.
In einer bevorzugten Ausführungsform liegen die Inhaltsstoffe des Probiotika enthaltenden Mikronährstoffkombinationsproduktes in Form wenigstens zwei getrennt vorliegender Produkte, vorzugsweise in Form wenigstens drei getrennt vorliegender Produkte und besonders bevorzugt in Form wenigstens vier getrennt vorliegender Produkte vor. In a preferred embodiment, the ingredients of the probiotics contain Micronutrient combination product in the form of at least two separately available Products, preferably in the form of at least three separate products and particularly preferably in the form of at least four separate products.
Erfindungsgemäß umfasst das Probiotika enthaltende Mikronährstoffkombinationsprodukt wenigstens ein getrennt vorliegendes erstes Produkt umfassend als wirksame Bestandteile probiotische Kulturen, vorzugsweise Bifidobacterium lactis, Bifidobacterium animalis, Lactococcus lactis, Enterococcus faecium, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus salivarius; und wenigstens ein zweites getrennt vorliegendes Produkt umfassend als wirksame Bestandteile Vitamin A, Vitamin C, Vitamin E, Vitamin B1, Vitamin B2, Niacin, Vitamin B6, Vitamin B12, Vitamin K1, Vitamin D3, Folsäure, Pantothensäure, Biotin, Selen, Eisen, Zink, Mangan, Kupfer, Chrom, Molybdän, Iod, Carotinoide, Bioflavonoide, Inulin. According to the invention, the probiotics-containing micronutrient combination product comprises at least one separately available first product comprising, as active components, probiotic cultures, preferably Bifidobacterium lactis, Bifidobacterium animalis, Lactococcus lactis, Enterococcus faecium, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus salivarius and at least one second separate product comprising as active ingredients vitamin A, vitamin C, vitamin E, vitamin B 1 , vitamin B 2 , niacin, vitamin B 6 , vitamin B 12 , vitamin K 1 , vitamin D 3 , folic acid, pantothenic acid, Biotin, selenium, iron, zinc, manganese, copper, chromium, molybdenum, iodine, carotenoids, bioflavonoids, inulin.
Ein weiterer vorteilhafter Effekt des Probiotika enthaltenden Mikronährstoffproduktes ergibt sich aus der Möglichkeit einer separaten Verabreichung der getrennt vorliegenden Produkte. Es ist bekannt, dass ein großer Teil der aufgenommenen probiotischen Bakterien die Passage durch den Magen-Darmtrakt nicht überleben und geringe Mengen lebender Milchsäurebakterien nicht ausreichen, den pH-Wert des Darms wirksam abzusenken. Erfindungsgemäß kann das Probiotika enthaltende Mikronährstoffkombinationsprodukt ein erstes Granulat umfassen, welches ausschließlich die probiotischen Kulturen umfasst, und ein zweites Granulat, das frei von Probiotika ist und die Vitamine, Spurenelemente, sekundäre Pflanzenstoffe und Inulin umfasst. Beispielsweise kann das die probiotischen Kulturen enthaltende Granulat vorzugsweise getrennt von den Mahlzeiten und dem zweiten Granulat verabreicht werden, so dass die Kulturen den Darm unter geringerer Schädigung durch zersetzende Säuren erreichen können. Diese Milchsäurebakterien können bereits im Dünndarm ihre Aktivität entfalten und durch ihre Milchsäureproduktion den pH-Wert im Dünn- und Dickdarm erniedrigen, so dass zu einem späteren Zeitpunkt die Resorption der den Darm erreichenden Spurenelemente durch die Aktivität der Milchsäurebakterien gesteigert wird. A further advantageous effect of the micronutrient product containing probiotics results the possibility of separate administration of the separately available products. It is known that a large part of the probiotic bacteria ingested the passage not survive through the gastrointestinal tract and small amounts of living Lactic acid bacteria are insufficient to effectively lower the intestinal pH. According to the invention, the micronutrient combination product containing probiotics can be a include first granules, which only includes the probiotic cultures, and a second granules that are free of probiotics and the vitamins, trace elements, secondary Includes plant substances and inulin. For example, the probiotic cultures containing granules preferably separately from the meals and the second granules are administered so that the cultures with less damage through the intestine can reach decomposing acids. These lactic acid bacteria can already be found in Develop their activity in the small intestine and, thanks to their lactic acid production, the pH in the Lower the small and large intestine so that the resorption of the Intestinal trace elements increased by the activity of lactic acid bacteria becomes.
Vorteilhaft ist weiterhin, dass sich eine hohe Zahl lebender Milchsäurebakterien im Darmtrakt ansiedeln kann, die durch die erfindungsgemäße Menge des Prebiotikums Inulin eine deutliche Erhöhung ihrer Lebensdauer zeigen. Diese Erhöhung der Lebensdauer verlängert die für eine effektive Resorption zur Verfügung stehende Zeitspanne. Dies ist insbesondere von großem Vorteil, da die Resorption der Vitalstoffe ihrerseits einige Zeit benötigt. Durch diese vorteilhaften Eigenschaften führt die Verwendung des erfindungsgemäßen Mittels auch zu einem verbesserten Blutplasmaspiegel der Mikronährstoffe. Another advantage is that there is a high number of live lactic acid bacteria in the intestinal tract can settle a by the amount of prebiotic inulin according to the invention show a significant increase in their lifespan. This increase in lifespan extends the time available for effective absorption. This is particularly so of great advantage, since the absorption of vital substances in turn takes some time. By the use of the agent according to the invention also leads to these advantageous properties to an improved blood plasma level of the micronutrients.
Vorzugsweise liegt das Probiotika enthaltende Mikronährstoffkombinationsprodukt umfassend wenigstens zwei Produkte mit unterschiedlicher Zusammensetzung in Form von 0 bis 10 Tabletten, vorzugsweise 1 bis 5 Tabletten, 0 bis 10 Kapseln, vorzugsweise 1 bis 5 Kapseln, 0 bis 5 Lösungen, vorzugsweise 1 bis 2 Lösungen und/oder 0 bis 5 Granulate, vorzugsweise 1 bis 3 Granulate, vor. The probiotics-containing micronutrient combination product is preferably located comprising at least two products with different compositions in the form of 0 up to 10 tablets, preferably 1 to 5 tablets, 0 to 10 capsules, preferably 1 to 5 Capsules, 0 to 5 solutions, preferably 1 to 2 solutions and / or 0 to 5 granules, preferably 1 to 3 granules.
Es hat sich gezeigt, dass Granulate insbesondere für den Darm die verträglichste Darreichungsform darstellen. Vorteilhaft ist darüber hinaus, dass diese Granulatform eine erhöhte Löslichkeit der Komponenten gewährleistet. Eine Einnahme in Form von Tabletten oder auch Filmtabletten kann dazu führen, dass die Inhaltsstoffe in Magen und Darm zeitlich unterschiedlich freigesetzt werden, was zu einer verzögerten und verschlechterten Resorption führen kann. It has been shown that granules are the most tolerable, especially for the intestine Present dosage form. It is also advantageous that this granulate form a Guaranteed increased solubility of the components. Ingestion in the form of tablets or even film-coated tablets can cause the ingredients in the stomach and intestines to time released differently, resulting in delayed and worsened absorption can lead.
Das Probiotika enthaltende Mikronährstoffkombinationsprodukt kann Zusätze umfassen, die die Bioverfügbarkeit, Löslichkeit und/oder Lösegeschwindigkeit verbessern und/oder Zusätze, ausgewählt aus der Gruppe umfassend Sprengmittel, Stoffe die die Haltbarkeit verbessern, geschmacksmaskierende und/oder geschmacksverbessernde Stoffe, Stoffe zur Erhöhung oder Senkung der Viskosität, aufweisen. The probiotics-containing micronutrient combination product may include additives that improve bioavailability, solubility and / or rate of dissolution and / or Additives selected from the group comprising explosives, substances that increase durability improve, taste masking and / or taste improving substances, substances for Increase or decrease the viscosity.
Das Probiotika enthaltende Mikronährstoffkombinationsprodukt kann Zusätze umfassen, die ausgewählt aus der Gruppe umfassend Dextrose, Maltodextrin, Maisstärke, natürliches Orangenaroma, Säuerungsmittel Zitronensäure, Gummi Arabicum, Fructooligosaccharide, Saccharin-Natrium und/oder Enzyme sein können. The probiotics-containing micronutrient combination product may include additives that selected from the group comprising dextrose, maltodextrin, corn starch, natural Orange flavor, acidifier citric acid, gum arabic, fructooligosaccharides, Saccharin sodium and / or enzymes can be.
Das erste getrennt vorliegende Produkt des Probiotika enthaltenden Mikronährstoffkombinationsproduktes kann, bezogen auf eine Tagesdosis, als wirksame Bestandteile ausschließlich 2 × 109 KBE probiotische Kulturen umfassen und das zweite getrennt vorliegende Produkt frei von probiotischen Kulturen sein und, bezogen auf eine Tagesdosis, 0,3-0,5 g Vitamine, 9-11 mg Spurenelemente, 2 g Prebiotika und 20-30 mg sekundärer Pflanzenstoffe umfassen. The first separate product of the micronutrient combination product containing probiotics, based on a daily dose, can comprise only 2 × 10 9 CFU probiotic cultures as active ingredients and the second separate product can be free of probiotic cultures and, based on a daily dose, 0.3- 0.5 g vitamins, 9-11 mg trace elements, 2 g prebiotics and 20-30 mg phytochemicals.
Die vorstehenden Mengenangaben sind lediglich beispielhaft, da das Mikronährstoffkombinationsprodukt auch Zusätze, Begleitstoffe und/oder Rohstoffe enthalten kann, die viel schwerer sind als der bzw. die eigentlichen Wirkstoffe, so dass die angegebenen Mengen bezogen auf eine Tagesdosis natürlich wesentlich niedriger oder auch höher sein können. The above quantities are only examples, since the Micronutrient combination product can also contain additives, accompanying substances and / or raw materials that much are heavier than the actual active ingredient (s), so that the amounts indicated based on a daily dose can of course be significantly lower or higher.
Die Probiotika können auch Fructooligosaccharide zur frühzeitigen Unterstützung der Kulturen enthalten. The probiotics can also be used for early support of fructooligosaccharides Cultures included.
Es hat sich gezeigt, dass das erfindungsgemäße Mittel eine verbesserte Wirkung bezüglich einer ausgewogenen Versorgung mit Vitaminen und Spurenelementen kombiniert mit optimiertem Nutzen und Verträglichkeit der probiotischen Kulturen aufweist. Durch die Eigenschaften und Merkmale der Vitamine, probiotischen Kulturen und des Prebiotikums Inulin weist die erfindungsgemäße Zusammensetzungen gegenüber üblichen Zusammensetzungen eine verbesserte ernährungsphysiologische Wirkung im Hinblick auf Störungen der Darmflora und des darmassoziierten Immunsystems auf. It has been shown that the agent according to the invention has an improved effect on a balanced supply of vitamins and trace elements combined with has optimized benefits and tolerability of probiotic cultures. Through the Properties and characteristics of the vitamins, probiotic cultures and the prebiotic Inulin has the compositions of the invention over conventional Compositions with regard to improved nutritional effects Disorders of the intestinal flora and the gut-associated immune system.
Das erfindungsgemäße Probiotika enthaltenende Mikronährstoffproduktes ist insbesondere
verwendbar zur diätetischen Behandlung bei Störungen, Beschwerden oder Krankheiten,
ausgewählt aus der Gruppe umfassend:
- - Allergien wie atopisches Ekzem, allergisches Asthma, Rhitinitis allergica, Nahrungsmittelallergie;
- - nach Chemo- und Strahlentherapie;
- - nach Antibiotikaeinnahme;
- - Gastroenteritiden;
- - Laktoseintoleranz;
- - chronisch-entzündliche Darmerkrankungen wie Colitis ulceros, Morbus Crohn;
- - hepatische Enzephalopathie; und/oder
- - Hypercholesterinämie.
- - allergies such as atopic eczema, allergic asthma, allergic rhitinitis, food allergy;
- - after chemotherapy and radiation therapy;
- - after taking antibiotics;
- - gastroenteritis;
- - lactose intolerance;
- - inflammatory bowel diseases such as ulcerative colitis, Crohn's disease;
- - hepatic encephalopathy; and or
- - hypercholesterolemia.
Es hat sich gezeigt, dass bei Verabreichung des erfindungsgemäßen Mikronährstoffproduktes allein oder in Kombination mit Arzneimitteln, Störungen, Beschwerden oder Krankheiten, wie oben angegeben, spürbar verringert und/oder schneller gelindert werden, oder gar nicht erst auftreten, im Vergleich zu üblichen im Stand der Technik bekannten Mikronährstoffkombinationsprodukten. Ohne auf eine bestimmte Theorie festgelegt zu sein, wird vermutet, dass die Kombination Enterococcus faecium und Milchsäurebakterien einen hierfür verantwortlich sein könnte, da Enterococcus faecium einen deutlich verbessernden Einfluss auf die Wirksamkeit der Milchsäurebakterien zeigt. Wie bereits beschrieben kann Enterococcus faecium den pH-Wert des Darmes schon im vorderen Bereich des Darmes ausgehend vom Magen senken. Bedingt durch diese Vorsäuerung wird die Wachstumsrate bzw. -geschwindigkeit der probiotischen Kulturen, insbesondere der Milchsäurebakterien, deutlich gesteigert, so dass der pH-Wert im Darm weiter sinkt. It has been shown that when the micronutrient product according to the invention is administered alone or in combination with medicines, disorders, complaints or illnesses, as stated above, noticeably reduced and / or alleviated faster, or not at all only occur compared to conventional ones known in the art Micronutrient combination products. Without being committed to any particular theory, it is believed that the combination of Enterococcus faecium and lactic acid bacteria is one of them could be responsible because Enterococcus faecium has a significantly improving influence shows the effectiveness of lactic acid bacteria. As already described Enterococcus faecium the pH of the intestine in the front area of the intestine lower starting from the stomach. The growth rate is due to this pre-acidification or speed of the probiotic cultures, especially the lactic acid bacteria, significantly increased so that the pH value in the intestine drops further.
Außerdem ist das erfindungsgemäße Probiotika enthaltenende Mikronährstoffprodukte als Nahrungsergänzungsmittel geeignet. Es hat sich gezeigt, dass insbesondere ein Mikronährstoffmangel bei Lebewesen, insbesondere Menschen, ausgeglichen werden kann. In addition, the micronutrient products containing probiotics according to the invention are as Food supplements suitable. It has been shown that in particular a Micronutrient deficiency in living things, especially humans, can be compensated for.
Der erste getrennt vorliegende Produktanteil des Probiotika enthaltenden
Mikronährstoffkombinationsproduktes kann als wirksame Bestandteile, bezogen auf eine
Tagesdosis:
- a) 5 × 108 - 5 × 109 KBE, bevorzugt 1-3 × 109 KBE, probiotische Kulturen ausgewählt aus der Gruppe umfassend Bifidobacterium lactis, Bifidobacterium animalis, Lactococcus lactis, Enterococcus faecium, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus salivarius;
- a) 1000-4000 IE, bevorzugt 2000-3000 IE, Vitamin A;
- b) 100-500 mg, bevorzugt 200-400 mg, Vitamin C;
- c) 10-80 mg, bevorzugt 25-45 mg, natürliches Vitamin E;
- d) 1-6 mg, bevorzugt 2-4 mg, Vitamin B1;
- e) 1-7 mg, bevorzugt 3-4 mg, Vitamin B2;
- f) 10-80 mg, bevorzugt 25-45 mg, Niacin;
- g) 1-7 mg, bevorzugt 3-4 mg Vitamin B6;
- h) 1-10 µg, bevorzugt 3-7 µg, Vitamin B12;
- i) 10-100 µg, bevorzugt 30-70 µg, Vitamin K1;
- j) 1-10 µg, bevorzugt 4-6 µg, Vitamin D3;
- k) 200-1000 µg, bevorzugt 400-800 µg, Folsäure;
- l) 5-50 mg, bevorzugt 10-25 mg, Panthothensäure;
- m) 50-300 µg, bevorzugt 150-225 µg, Biotin;
- n) 5-80 µg, bevorzugt 20-50 µg, Selen;
- o) 0,5-10 mg, bevorzugt 1-4 mg, Eisen;
- p) 3-15 mg, bevorzugt 5-10 mg, Zink;
- q) 0.3-3 mg, bevorzugt 0,5-2 mg, Mangan;
- r) 0,2-3 mg, bevorzugt 0,4-2 mg, Kupfer;
- s) 10-100 µg, bevorzugt 20-50 µg, Chrom;
- t) 10-100 µg, bevorzugt 30-60 µg, Molybdän;
- u) 50-200 µg, bevorzugt 100-150 µg, Iod;
- v) 1-15 mg, bevorzugt 3-7 mg, Carotinoide;
- w) 5-50 mg, bevorzugt 15-30 mg, Bioflavonoide;
- x) 1-6 g, bevorzugt 2-4 g, Inulin.
- a) 5 × 10 8 - 5 × 10 9 CFU, preferably 1-3 × 10 9 CFU, probiotic cultures selected from the group comprising Bifidobacterium lactis, Bifidobacterium animalis, Lactococcus lactis, Enterococcus faecium, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus salivarius;
- a) 1000-4000 IU, preferably 2000-3000 IU, vitamin A;
- b) 100-500 mg, preferably 200-400 mg, vitamin C;
- c) 10-80 mg, preferably 25-45 mg, natural vitamin E;
- d) 1-6 mg, preferably 2-4 mg, vitamin B 1 ;
- e) 1-7 mg, preferably 3-4 mg, vitamin B 2 ;
- f) 10-80 mg, preferably 25-45 mg, niacin;
- g) 1-7 mg, preferably 3-4 mg of vitamin B 6 ;
- h) 1-10 µg, preferably 3-7 µg, vitamin B 12 ;
- i) 10-100 µg, preferably 30-70 µg, vitamin K 1 ;
- j) 1-10 µg, preferably 4-6 µg, vitamin D 3 ;
- k) 200-1000 µg, preferably 400-800 µg, folic acid;
- l) 5-50 mg, preferably 10-25 mg, pantothenic acid;
- m) 50-300 µg, preferably 150-225 µg, biotin;
- n) 5-80 µg, preferably 20-50 µg, selenium;
- o) 0.5-10 mg, preferably 1-4 mg, iron;
- p) 3-15 mg, preferably 5-10 mg, zinc;
- q) 0.3-3 mg, preferably 0.5-2 mg, manganese;
- r) 0.2-3 mg, preferably 0.4-2 mg, copper;
- s) 10-100 µg, preferably 20-50 µg, chromium;
- t) 10-100 µg, preferably 30-60 µg, molybdenum;
- u) 50-200 µg, preferably 100-150 µg, iodine;
- v) 1-15 mg, preferably 3-7 mg, carotenoids;
- w) 5-50 mg, preferably 15-30 mg, bioflavonoids;
- x) 1-6 g, preferably 2-4 g, inulin.
Der Gegenstand der vorliegenden Erfindung wird anhand des nachfolgenden Beispiels näher erläutert. The object of the present invention is illustrated by the following example explained.
Probiotika enthaltendes Mikronährstoffkombinationsprodukt umfassend zwei Granulate I und
II unterschiedlicher Zusammensetzung:
Granulat I:
2 × 109 KBE probiotische Kulturen, umfassend Bifidobacterium lactis bzw. animalis,
Lactococcus lactis, Enterococcus faecium, Lactobacillus acidophilus, Lactobacillus casei,
Lactobacillus salivarius;
Als Hilfsstoffe werden Maisstärke, Maltodextrin, Fructooligosaccharide, und/oder Enzyme
zugesetzt.
Granulat II:
- - 2500 IE Vitamin A
- - 300 mg Vitamin C;
- - 36 mg natürliches Vitamin E;
- - 3 mg Vitamin B1;
- - 3,6 mg Vitamin B2;
- - 35 mg Niacin;
- - 3,6 mg Vitamin B6;
- - 6 µg Vitamin B12;
- - 60 µg Vitamin K1;
- - 5 µg Vitamin D3;
- - 800 µg Folsäure;
- - 18 mg Panthothensäure;
- - 180 µg Biotin;
- - 30 µg Selen;
- - 2 mg Eisen;
- - 7 mg Zink;
- - 500 µg Mangan;
- - 500 µg Kupfer;
- - 30 µg Chrom;
- - 50 µg Molybdän;
- - 100 µg Iod;
- - 5 mg Carotinoide;
- - 20 mg Bioflavonoide;
- - 2 g Inulin.
Granules I:
2 × 10 9 CFU probiotic cultures, comprising Bifidobacterium lactis or animalis, Lactococcus lactis, Enterococcus faecium, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus salivarius;
Corn starch, maltodextrin, fructooligosaccharides and / or enzymes are added as auxiliary substances.
Granules II:
- - 2500 IU of vitamin A.
- - 300 mg of vitamin C;
- - 36 mg of natural vitamin E;
- - 3 mg vitamin B 1 ;
- - 3.6 mg of vitamin B 2 ;
- - 35 mg of niacin;
- - 3.6 mg vitamin B 6 ;
- - 6 µg of vitamin B 12 ;
- - 60 µg of vitamin K 1 ;
- - 5 µg of vitamin D 3 ;
- - 800 µg folic acid;
- - 18 mg pantothenic acid;
- - 180 µg biotin;
- - 30 µg selenium;
- - 2 mg iron;
- - 7 mg zinc;
- - 500 µg manganese;
- - 500 µg copper;
- - 30 µg chromium;
- - 50 µg molybdenum;
- - 100 µg iodine;
- - 5 mg carotenoids;
- - 20 mg bioflavonoids;
- - 2 g inulin.
Als Hilfsstoffe werden Dextrose, Maltodextrin, Maisstärke, natürliches Orangenaroma, Säuerungsmittel Zitronensäure, und/oder Gummi Arabicum und Saccharin-Natrium zugesetzt. Dextrose, maltodextrin, corn starch, natural orange aroma, Acidifier citric acid, and / or gum arabic and saccharin sodium added.
Die Gewichtsangaben, wenn nicht anders angegeben, beziehen sich auf eine Tagesdosis.
Tabelle I
Unless otherwise stated, the weight data relate to a daily dose. Table I
Tabelle I zeigt einen Vergleich des Effektes üblicher Mikronährstoffprodukte verschiedener Zusammensetzungen auf das Immunsystem. Der Tabelle I ist zu entnehmen, dass eine deutliche Stimulierung des Immunsystems durch die kombinierte Gabe probiotischer Kulturen und des Prebiotikums Inulin insbesondere probiotischer Kulturen, Inulin und Spurenelementen erreicht wurde. Es zeigt sich, dass eine Versorgung, die neben den probiotischen Kulturen und Vitaminen insbesondere eine erfindungsgemäße Kombination von probiotischen Kulturen, Vitaminen, Spurenelementen und Inulin aufweist, eine verbesserte Wirkung im Hinblick auf die Stärkung des gesamten körpereigenen Immunsystems auf. Table I shows a comparison of the effect of common micronutrient products of various Compositions on the immune system. It can be seen from Table I that a significant stimulation of the immune system through the combined administration of probiotic Cultures and the prebiotic inulin, in particular probiotic cultures, inulin and Trace elements was reached. It turns out that a supply that is in addition to the probiotic cultures and vitamins in particular a combination of has probiotic cultures, vitamins, trace elements and inulin, an improved Effect in terms of strengthening the entire body's immune system.
Claims (18)
das zweite getrennt vorliegende Produkt, bezogen auf eine Tagesdosis, als wirksame Bestandteile die Stoffe umfasst:
the second separate product, based on a daily dose, comprises the following as active ingredients:
Allergien wie atopisches Ekzem, allergisches Asthma, Rhitinitis allergica, Nahrungsmittelallergie;
nach Chemo- und Strahlentherapie;
nach Antibiotikaeinnahme;
Gastroenteritiden;
Laktoseintoleranz;
chronisch-entzündliche Darmerkrankungen wie Colitis ulceros, Morbus Crohn;
hepatische Enzephalopathie; und/oder
Hypercholesterinämie. 17. Use of a micronutrient product containing probiotics according to one of the preceding claims for the preparation of an agent for the dietary treatment of disorders, complaints or diseases, selected from the group comprising:
Allergies such as atopic eczema, allergic asthma, allergic rhitinitis, food allergy;
after chemotherapy and radiation therapy;
after taking antibiotics;
gastroenteritis;
Lactose intolerance;
inflammatory bowel diseases such as ulcerative colitis, Crohn's disease;
hepatic encephalopathy; and or
Hypercholesterolemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10206995.6A DE10206995B4 (en) | 2002-02-19 | 2002-02-19 | Micronutrient combination product with pro- and prebiotics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10206995.6A DE10206995B4 (en) | 2002-02-19 | 2002-02-19 | Micronutrient combination product with pro- and prebiotics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE10206995A1 true DE10206995A1 (en) | 2003-09-04 |
| DE10206995B4 DE10206995B4 (en) | 2014-01-02 |
Family
ID=27674761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10206995.6A Expired - Fee Related DE10206995B4 (en) | 2002-02-19 | 2002-02-19 | Micronutrient combination product with pro- and prebiotics |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE10206995B4 (en) |
Cited By (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005039319A2 (en) * | 2003-10-24 | 2005-05-06 | N.V. Nutricia | Synbiotic composition for infants |
| EP1602716A1 (en) * | 2004-06-03 | 2005-12-07 | BioMan S.r.l. | Selenium-enriched biomass, method of preparing thereof and probiotic and nutraceutic products including said biomass |
| WO2006091103A3 (en) * | 2005-02-28 | 2006-10-26 | Nutricia Nv | Nutritional composition with probiotics |
| AT501919A1 (en) * | 2005-06-14 | 2006-12-15 | Erber Ag | PROBIOTIC, HEALTH OR BZW. PERFORMANCE-SUPPORTING FOOD, FEEDINGSTUFF AND / OR DRINKING WATER SUPPLEMENT AND ITS USE |
| DE102006062250A1 (en) * | 2006-12-22 | 2008-06-26 | Roland Saur-Brosch | Use of a composition of minerals and / or vitamins and optionally acetogenic and / or butyrogenic bacteria for oral or rectal administration for the treatment and prevention of abdominal discomfort |
| ITMI20092327A1 (en) * | 2009-12-29 | 2011-06-30 | Giuliani Spa | PHARMACEUTICAL OR DIETETIC COMPOSITION FOR THE TREATMENT OF ATOPIA |
| EP1699474B2 (en) † | 2003-12-24 | 2013-10-23 | Ferrosan A/S | Probiotic tablet formulations |
| WO2016046727A1 (en) * | 2014-09-23 | 2016-03-31 | Dom Terry International S.R.L. | Prebiotic inulin based preparation |
| WO2018227146A1 (en) * | 2017-06-08 | 2018-12-13 | Allergyintellect, Inc | Vitamin d compounds and methods of using the same |
| WO2019060661A1 (en) * | 2017-09-22 | 2019-03-28 | Iowa State University Research Foundation, Inc. | Probiotic compositions for production of dopamine |
| US10322151B2 (en) | 2015-06-15 | 2019-06-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10357520B2 (en) | 2015-11-20 | 2019-07-23 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10391130B2 (en) | 2015-06-15 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10391128B2 (en) | 2015-11-23 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10456444B2 (en) | 2014-12-23 | 2019-10-29 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| US10471108B2 (en) | 2015-11-20 | 2019-11-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10485830B2 (en) | 2016-12-12 | 2019-11-26 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10493112B2 (en) | 2015-06-15 | 2019-12-03 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10500237B2 (en) | 2015-06-15 | 2019-12-10 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10583158B2 (en) | 2016-03-04 | 2020-03-10 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10610549B2 (en) | 2016-07-13 | 2020-04-07 | 4D Pharma Plc | Composition comprising bacterial strains |
| US10736926B2 (en) | 2015-06-15 | 2020-08-11 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10744166B2 (en) | 2015-11-23 | 2020-08-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10851137B2 (en) | 2013-04-10 | 2020-12-01 | 4D Pharma Research Limited | Polypeptide and immune modulation |
| US10987387B2 (en) | 2017-05-24 | 2021-04-27 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| US11007233B2 (en) | 2017-06-14 | 2021-05-18 | 4D Pharma Research Limited | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
| US11013773B2 (en) | 2011-07-14 | 2021-05-25 | 4D Pharma Research Limited | Lactic acid bacterial strains |
| US11123379B2 (en) | 2017-06-14 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11123378B2 (en) | 2017-05-22 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11224620B2 (en) | 2016-07-13 | 2022-01-18 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US11266698B2 (en) | 2011-10-07 | 2022-03-08 | 4D Pharma Research Limited | Bacterium for use as a probiotic for nutritional and medical applications |
| US11723933B2 (en) | 2014-12-23 | 2023-08-15 | Cj Bioscience, Inc. | Composition of bacteroides thetaiotaomicron for immune modulation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0931543T3 (en) * | 1997-12-19 | 2002-06-17 | Merck Patent Gmbh | Multilayer tablets containing probiotic microorganisms such as lactobacilli or bifidobacteria |
| EP1102595A2 (en) * | 1998-08-07 | 2001-05-30 | Ganeden Biotech, Inc. | Methods for increasing the solubility of nutritional materials using probiotic lactic acid-producing bacteria |
| ID29150A (en) * | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | USE OF LACTOBACILLUS SALIVARIUS |
| DE19937361A1 (en) * | 1999-08-12 | 2001-02-22 | Merck Patent Gmbh | Oral dosage form |
| DE10008990A1 (en) * | 2000-01-11 | 2001-07-12 | Vitafood Ag St Gallen | Milk-free, oligofructose-containing prebiotic instant powder for use as a food supplement or in drink production also contains minerals, trace elements or plant extracts |
| CN1423528A (en) * | 2000-04-18 | 2003-06-11 | 雀巢制品公司 | Nutritional modules |
| FI109602B (en) * | 2001-01-25 | 2002-09-13 | Valio Oy | Probiotkombination |
-
2002
- 2002-02-19 DE DE10206995.6A patent/DE10206995B4/en not_active Expired - Fee Related
Cited By (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005039319A2 (en) * | 2003-10-24 | 2005-05-06 | N.V. Nutricia | Synbiotic composition for infants |
| WO2005039319A3 (en) * | 2003-10-24 | 2005-08-04 | Nutricia Nv | Synbiotic composition for infants |
| EP2033529A3 (en) * | 2003-10-24 | 2013-10-02 | N.V. Nutricia | Synbiotic composition for infants |
| EP1699474B2 (en) † | 2003-12-24 | 2013-10-23 | Ferrosan A/S | Probiotic tablet formulations |
| US10172793B2 (en) | 2003-12-24 | 2019-01-08 | Ferrosan A.S. | Probiotic tablet formulations |
| WO2005118776A1 (en) * | 2004-06-03 | 2005-12-15 | Bioman S.R.L. | Selenium-enriched biomass, method for preparing thereof and probiotic and nutraceutical products including said biomass |
| US7666638B2 (en) | 2004-06-03 | 2010-02-23 | Bioman S.R.L. | Selenium-enriched biomass, method for preparing thereof and probiotic and nutraceutical products including said biomass |
| EP1602716A1 (en) * | 2004-06-03 | 2005-12-07 | BioMan S.r.l. | Selenium-enriched biomass, method of preparing thereof and probiotic and nutraceutic products including said biomass |
| WO2006091103A3 (en) * | 2005-02-28 | 2006-10-26 | Nutricia Nv | Nutritional composition with probiotics |
| US10071125B2 (en) | 2005-02-28 | 2018-09-11 | N.V. Nutricia | Nutritional composition with probiotics |
| EP2351492A1 (en) * | 2005-02-28 | 2011-08-03 | N.V. Nutricia | Nutritional composition with probiotics |
| US9314047B2 (en) | 2005-02-28 | 2016-04-19 | N.V. Nutricia | Nutritional composition with probiotics |
| EP2805625A3 (en) * | 2005-02-28 | 2015-03-25 | N.V. Nutricia | Nutritional composition with probiotics |
| AT501919A1 (en) * | 2005-06-14 | 2006-12-15 | Erber Ag | PROBIOTIC, HEALTH OR BZW. PERFORMANCE-SUPPORTING FOOD, FEEDINGSTUFF AND / OR DRINKING WATER SUPPLEMENT AND ITS USE |
| AT501919B1 (en) * | 2005-06-14 | 2008-09-15 | Erber Ag | PROBIOTIC, HEALTH OR BZW. PERFORMANCE-ADDING FEED AND / OR DRINKING WATER SUPPLEMENT FOR ANIMALS AND ITS USE |
| DE102006062250A1 (en) * | 2006-12-22 | 2008-06-26 | Roland Saur-Brosch | Use of a composition of minerals and / or vitamins and optionally acetogenic and / or butyrogenic bacteria for oral or rectal administration for the treatment and prevention of abdominal discomfort |
| WO2008077614A2 (en) | 2006-12-22 | 2008-07-03 | Roland Saur-Brosch | Use of a composition made of mineral nutrients and optionally acetogenic and/or butyrogenic bacteria in order to avoid or reduce the formation of gas in the large intestine of a mammal and the resulting abdominal problems |
| ITMI20092327A1 (en) * | 2009-12-29 | 2011-06-30 | Giuliani Spa | PHARMACEUTICAL OR DIETETIC COMPOSITION FOR THE TREATMENT OF ATOPIA |
| US11013773B2 (en) | 2011-07-14 | 2021-05-25 | 4D Pharma Research Limited | Lactic acid bacterial strains |
| US11266698B2 (en) | 2011-10-07 | 2022-03-08 | 4D Pharma Research Limited | Bacterium for use as a probiotic for nutritional and medical applications |
| US11414463B2 (en) | 2013-04-10 | 2022-08-16 | 4D Pharma Research Limited | Polypeptide and immune modulation |
| US10851137B2 (en) | 2013-04-10 | 2020-12-01 | 4D Pharma Research Limited | Polypeptide and immune modulation |
| WO2016046727A1 (en) * | 2014-09-23 | 2016-03-31 | Dom Terry International S.R.L. | Prebiotic inulin based preparation |
| US11723933B2 (en) | 2014-12-23 | 2023-08-15 | Cj Bioscience, Inc. | Composition of bacteroides thetaiotaomicron for immune modulation |
| US10973872B2 (en) | 2014-12-23 | 2021-04-13 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| US10456444B2 (en) | 2014-12-23 | 2019-10-29 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| US11040075B2 (en) | 2015-06-15 | 2021-06-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10736926B2 (en) | 2015-06-15 | 2020-08-11 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10493112B2 (en) | 2015-06-15 | 2019-12-03 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10500237B2 (en) | 2015-06-15 | 2019-12-10 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11433106B2 (en) | 2015-06-15 | 2022-09-06 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11389493B2 (en) | 2015-06-15 | 2022-07-19 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11331352B2 (en) | 2015-06-15 | 2022-05-17 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11273185B2 (en) | 2015-06-15 | 2022-03-15 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10864236B2 (en) | 2015-06-15 | 2020-12-15 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10391130B2 (en) | 2015-06-15 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10744167B2 (en) | 2015-06-15 | 2020-08-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10322151B2 (en) | 2015-06-15 | 2019-06-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10780134B2 (en) | 2015-06-15 | 2020-09-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10471108B2 (en) | 2015-11-20 | 2019-11-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10610550B2 (en) | 2015-11-20 | 2020-04-07 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11058732B2 (en) | 2015-11-20 | 2021-07-13 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10357520B2 (en) | 2015-11-20 | 2019-07-23 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10744166B2 (en) | 2015-11-23 | 2020-08-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10391128B2 (en) | 2015-11-23 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10583158B2 (en) | 2016-03-04 | 2020-03-10 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10610548B2 (en) | 2016-07-13 | 2020-04-07 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US11224620B2 (en) | 2016-07-13 | 2022-01-18 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10960031B2 (en) | 2016-07-13 | 2021-03-30 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10967010B2 (en) | 2016-07-13 | 2021-04-06 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10610549B2 (en) | 2016-07-13 | 2020-04-07 | 4D Pharma Plc | Composition comprising bacterial strains |
| US10543238B2 (en) | 2016-12-12 | 2020-01-28 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10485830B2 (en) | 2016-12-12 | 2019-11-26 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10898526B2 (en) | 2016-12-12 | 2021-01-26 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US11382936B2 (en) | 2017-05-22 | 2022-07-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11123378B2 (en) | 2017-05-22 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11376284B2 (en) | 2017-05-22 | 2022-07-05 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10987387B2 (en) | 2017-05-24 | 2021-04-27 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| US11419882B2 (en) | 2017-06-08 | 2022-08-23 | Allergyintellect, Inc | Vitamin D compounds and methods of using the same |
| WO2018227146A1 (en) * | 2017-06-08 | 2018-12-13 | Allergyintellect, Inc | Vitamin d compounds and methods of using the same |
| US11123379B2 (en) | 2017-06-14 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11007233B2 (en) | 2017-06-14 | 2021-05-18 | 4D Pharma Research Limited | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
| US11660319B2 (en) | 2017-06-14 | 2023-05-30 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11779613B2 (en) | 2017-06-14 | 2023-10-10 | Cj Bioscience, Inc. | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
| US11357803B2 (en) * | 2017-09-22 | 2022-06-14 | Iowa State University Research Foundation, Inc. | Probiotic compositions for production of dopamine |
| WO2019060661A1 (en) * | 2017-09-22 | 2019-03-28 | Iowa State University Research Foundation, Inc. | Probiotic compositions for production of dopamine |
| US20220313751A1 (en) * | 2017-09-22 | 2022-10-06 | Iowa State University Research Foundation, Inc. | Probiotic compositions for production of dopamine |
Also Published As
| Publication number | Publication date |
|---|---|
| DE10206995B4 (en) | 2014-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE10206995B4 (en) | Micronutrient combination product with pro- and prebiotics | |
| DE60122570T2 (en) | FOOD COMPOSITION FOR IMMUNE DISEASE | |
| DE69936740T2 (en) | Oligosaccharide and probiotics containing preparation | |
| EP0901371B1 (en) | Alteration of microbial populations in the gastrointestinal tract | |
| EP2124972B1 (en) | Use of a composition made of mineral nutrients and optionally acetogenic and/or butyrogenic bacteria in order to avoid or reduce the formation of gas in the large intestine of a mammal and the resulting abdominal problems | |
| DE60024438T2 (en) | Sportlergetränk with trace elements and viable Lactobacilli | |
| US20150290140A1 (en) | Compositions comprising microparticles and probiotics to deliver a synergistic immune effect | |
| DE202016008919U1 (en) | Compositions for use in the prevention or treatment of gastrointestinal infection / inflammation in infants or young children | |
| DE202010008308U1 (en) | Composition for nutritive supplementation or treatment for urinary tract infections and / or bacterial inflammation of the mucous membranes | |
| WO2018181380A1 (en) | Edible composition for intestinal bacteria | |
| CN110101079A (en) | Alimentation composition and application thereof containing magnesium threonate | |
| WO2012089782A1 (en) | Fiber and probiotics for reducing intestinal symptoms related to stress | |
| WO2019199708A1 (en) | Probiotic beverages containing a cannabinoid | |
| EP2228067A1 (en) | Probiotic compound and use of same | |
| WO2012089784A1 (en) | Fiber and probiotics for reducing intestinal symptoms related to chronic stress | |
| CA2994347A1 (en) | Methods and compositions using bifidobacterium longum to modulate emotional reactivity and treat or prevent sub-clinical mood disturbances | |
| WO2021103776A1 (en) | Compound preparation having auxiliary effect of preventing and treating psychological depression in children and adolescents | |
| EP1952703B1 (en) | Product including living probiotic micro organisms | |
| EP1917969A1 (en) | Compositions for preventing depletion of the intestinal flora and organ damage following antibiotic treatment | |
| Kumar et al. | Health-promoting probiotic functional foods | |
| DE202020002846U1 (en) | Preparation of an innovative multi-component powder mixture with a synbiotic enhanced overall effect | |
| WO2023118550A1 (en) | Synbiotic for use in a therapy method | |
| CH713686A2 (en) | Composition and appropriate dietary supplement. | |
| DE202023101702U1 (en) | Composition of bacterial strains | |
| WO2017103282A1 (en) | Method for producing fruit-oat drinks, and fruit-oat drinks produced in this manner |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| R019 | Grant decision by federal patent court | ||
| R020 | Patent grant now final | ||
| R020 | Patent grant now final |
Effective date: 20141003 |
|
| R119 | Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee | ||
| R079 | Amendment of ipc main class |
Free format text: PREVIOUS MAIN CLASS: A23L0001300000 Ipc: A23L0033135000 |